Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Klatskin Tumor 1Cirrhosis, Familial, with Pulmonary Hypertension 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Gemcitabine 23Cisplatin 16pembrolizumab 6Fluorouracil 6pemigatinib 4Radiotherapy 3Oxaliplatin 3Leucovorin 3Drug Therapy 3infigratinib 2durvalumab 2ceritinib 2aldesleukin 2Radiosurgery 2Photochemotherapy 2Nivolumab 2Liver Transplantation 2Dexamethasone 2Cholangiopancreatography, Endoscopic Retrograde 2Carboplatin 2Capecitabine 2trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1spartalizumab 1seribantumab 1perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane) 1peginterferon alfa-2b 1pazopanib 1padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cholangiocarcinoma × gemcitabine-oxaliplatin regimen × Clear all
NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Peking University

Phase 2 Terminated
1 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡